About the Department
The Nuclear Medicine and Molecular Imaging Program includes a vibrant community of physicians, scientists and technologists among others who are actively involved in clinical care, research, and community outreach programs. We work together providing imaging, therapy, and education at several hospitals in Hamilton including the Hamilton General Hospital, the Juravinski Cancer Centre, the McMaster University Medical Centre, and St. Joseph’s Healthcare Hamilton. We also provide clinical services at Cambridge Memorial Hospital in Cambridge, Ontario.
What is Nuclear Medicine?
Nuclear medicine relies on radiopharmaceuticals, radioactive pharmaceuticals that have met legal requirements for administration to patients. These radiopharmaceuticals can localize metabolic processes and pinpoint sites of disease within organs and/or organ systems. They can also be used in certain cases to treat disease. Typically, a small amount of a radiopharmaceutical is given to a patient by injection, ingestion, or inhalation. The radiopharmaceutical follows a particular metabolic pathway or is attracted to a particular site of disease and releases small amounts of energy (radiation) that can be detected outside of the body by special scanners. These scanners record the movement and localization of radiopharmaceuticals in the body as images. The resulting images are evaluated by physicians to diagnose and treat disease.
About the Chief – Dr. Amit Singnurkar, MDCM, MPH, FRCPC (Interim)
Dr. Singnurkar completed medical school and nuclear medicine residency at McGill University, followed by a fellowship in nuclear oncology and PET/CT at Memorial Sloan Kettering Cancer Centre. He entered into practice in 2009, followed shortly after with the completion of a master’s degree in clinical effectiveness at the Harvard TH Chan School of Public Health. He now practices nuclear medicine and molecular imaging in Hamilton and has previously served as site lead at St. Joseph’s Healthcare Hamilton and the Hamilton General Hospital, in addition to being the program lead for nuclear cardiology and cardiac PET. He is a long serving member of the PET steering committee at Cancer Care Ontario and has authored practice guidelines with the program for evidence-based medicine. Dr. Singnurkar’s main interest is in policy development to ensure the provision of appropriate and high quality imaging tied to improved health outcomes. His other interests include translational research of novel radiotracers and imaging techniques primarily in the fields of oncology, cardiology and neurology.
email@example.com, 905-521-2100 ext. 73452